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Table 1: Clinical treatment outcome definitions for 100 cases of MDR-TB diagnosed in London and West Midlands between 2008 and 
2014. 
Successful outcomes Neutral outcomes Negative outcomes 
Treatment completed: completed the 
duration as per treating physician’s choice 
Transferred overseas: care transferred to a 
medical team overseas 
Death: any death for any cause during the 
course of treatment 
 Deportation/repatriation: removal by UKBA  
out of the UK 
Lost to follow up: Any patient lost within 
the UK 
  Lost overseas: Any patient known to have 
gone overseas without transfer of care to 
a medical team.  
  Treatment stopped: any patient who does 
not complete the prescribed duration of 
treatment for any reason and does not fit 
the ‘recurrent defaulter’ definition. 
  Recurrent defaulter: any patient who has 
started MDR-TB treatment more than 
twice and has not completed any of the 
treatment courses due to poor adherence. 
   
UKBA=UK Border Authority. Definitions adapted from Anderson et 2013 (14) 
  
Table 2: Discharge sputum status of last sputum obtained before discharge for 100 cases of MDR-TB diagnosed in London and West 
Midlands between 2008 and 2014. 
Smear positive  A positive sputum smear for AAFB taken within 21 days from discharge and no negative 
cultures available at the time of discharge. 
Smear negative A smear negative result taken under 42 days from discharge (and thus no cultures negative at 
6 weeks available). 
Smear negative plus one culture 
negative 
The last sputum taken was smear negative and a smear and culture negative result from a 
sputum taken over 42 days from discharge is also available. 
Smear negative plus over one 
culture negative 
The last sputum taken was smear negative and more than one smear and culture negative 
results from sputa taken over 42 days from discharge and at least 7 days apart are available. 
No sputum sent within 70 days 
from discharge 
No samples for over 70 days from discharge and the last sputum result was culture positive. 
No sputum sent No sputum sent during diagnosis or admission. 
MDR-TB= Multidrug resistant tuberculosis, AAFB=acid alcohol fast bacilli 
  
Table 3: Demographics and background information for 100 cases of MDR-TB diagnosed in London and West Midlands between 2008 
and 2014.  
Characteristic  Number (% unless 
otherwise indicated) 
Median age in years (IQR) (n=100)  28.5 (24-38) 
Male gender (n=100)  68/100 (68) 
HIV infected (n=100)  5/100 (5) 
Recent immigrant (< 2 years) (n=98)  39/98 (40) 
Country of birth (n=100) UK 12/100 (12) 
 Western and Northern 
Europe other  
1/100    (1) 
 Chinese subcontinent 10/100 (10) 
 Indian subcontinent 37/100 (37) 
 Africa 18/100 (18) 
 Eastern Europe + Russia 22/100 (22) 
Recourse to public funds (n=93)  57/93 (61) 
Admitted from prison (n=100)  5/100 (5) 
Previous DST fully sensitive TB in the 
UK (n=100) 
 7/100 (7) 
Type of TB (n=100) MDR-TB 79/100  (79) 
 MDR-TB +FLQ resistance 13/100 (13) 
 XDR-TB* 8/100   (8) 
Prothionamide resistance**(n=99)  36/99 (36) 
Ethambutol resistance** (n=100)  53/100 (53) 
Pyrazinamide resistance** (n=100)  44/100 (44) 
Resistance to all injectable agents 
*** 
 6/100 (6) 
Location of TB (n=100) Pulmonary 45/100 (45) 
 Extra-pulmonary only 32/100 (32) 
 Both pulmonary and extra-
pulmonary 
23/100 (23) 
Site/s of extra-pulmonary cases (not 
exclusive) (n=55)  
Spinal 14/55 (25) 
 Lymph node 17/55 (31) 
 Pleural/empyema 7/55 (13) 
 Musculoskeletal (excludes 
spinal) 
7/55 (13) 
 Pericardial 2/55 (4) 
 Abdominal  4/55 (7) 
 Millary (chest radiology) 1/55 (2) 
 CNS (tuberculoma) 1/55 (25) 
 urine 2/55 (4) 
Culture confirmed (n=100) (any site)  98/100 (98) 
Smear positive sputum (n=68)  47/68 (69) 
Culture positive sputum (n=68)  63/68 (93) 
Unilateral parenchymal changes   
where baseline CXR available 
(n=65)**** 
 27/65 (42) 
Bilateral parenchymal changes  
where baseline CXR available 
(n=65)**** 
 31/65 (48) 
Unilateral cavities where baseline 
CXR available (n=65)**** 
 20/65 (31) 
Bilateral cavities where baseline CXR 
available (n=65)**** 
 5/65 (8) 
IQR=interquartile range, TB=tuberculosis, CXR= chest radiograph, MDR-TB= multidrug resistant tuberculosis, XDR-TB = extensively 
resistant tuberculosis, MDR-TB +FLQ= MDR-TB plus fluroquinolone resistance, n= number of cases for whom information is available. 
*Includes a patient that started with MDR-TB and converted to XDR-TB during treatment. **Resistance based on phenotypic drug 
sensitivity testing (DST) and includes two patients treated on epidemiological grounds where resistance pattern of source patient was 
known. ***All injectable agents=amikacin, capreomycin, kanamycin, streptomycin. ****Those negative on chest radiograph were 
diagnosed either on sputum culture or on computed tomography as pulmonary TB.  
 
  
Table 4: Initial drug choices for 100 cases of MDR-TB diagnosed in London and West Midlands between 2008 and 2014. 
Characteristic Total 
 
 
(% unless 
otherwis
e stated) 
 
 
 
First half 
cohort 
2008-2011 
 
(% unless 
otherwise 
stated) 
 
 
 
Second half 
cohort 
2011-2014 
 
(% unless 
otherwise 
stated) 
 
 
 
P 
Number started first on RHZE before 
switching to an MDR-TB regimen (n=97) 
 
 74 (76) 38 (78) 36 (75) 0.77 
Number of days between RHZE and start of 
MDR-TB regimen  (n=68) (IQR) 
 28(11-55) 35 (14-61) 
 
19 (7-38) 
 
0.05 
Number of days between RHZE  and start of 
MDR-TB regimen for smear positive 
patients only (n=31) (IQR) 
 18 (3-40) 
 
25 (3-50) 
 
18 (4-33) 
 
0.55 
Reason for starting a MDR-TB regimen 
(n=100) 
Phenotypic Rifampicin resistance 
on culture  
(18=smear positive) 
53 (53) 34 (69) 19 (38) <0.01 
 Molecular rifampicin resistance- 
on sputum (22=smear positive) 
23 (23) 10 (20) 13 (26) 0.48 
 Molecular rifampicin resistance- 
on a culture 
(4=smear positive) 
17 (17) 4 (8) 13 (26) 0.02 
 Epidemiological contact or 
previous history of MDR-TB 
(2=smear positive) 
7 (7) 2 (4) 5 (10) 0.24 
Starting regimen (n=98) Injectable, FLQ, +/-EZ, Pto, Cs (1 
plus Li) 
42 (43) 17 (34) 25 (52)  
 Injectable, FLQ, +/-EZ, Pto, Cs + 
PAS (2 plus Li, 1 plus C) 
13 (13) 4 (8) 9(19)  
 Injectable, FLQ, +/-EZ, Pto (1 plus 
Li) 
10 (10) 7 (14) 3 (6)  
 Injectable, FLQ, +/-EZ, Pto, PAS (1 
plus Li) 
10 (10) 7 (14) 3 (6)  
 Injectable, FLQ, +/-EZ, PAS CS (2 
plus Li, 1 plus C) 
3 1 2  
 Injectable, FLQ, +/-EZ, PAS 5 5 0  
 Injectable, FLQ, EZ, Cs (2 plus Li + 
C) 
4 1 3  
 Injectable, FLQ, +/-EZ, 3 1 2  
 No FLQ 6 5 1  
Sub-optimal regimen at start* due to 
underestimating resistance (n=99) 
 14 (14) 
 
8 (16) 6 (12)  
Drug use at any time (n=100) no injectable 2  2 0  
 pyrazinamide 91 42 49  
 ethambutol  72 33 39  
 amikacin  65 32 33  
 capreomycin 52 22 30  
 streptomycin 3 3 0  
 moxifloxacin (400mg) 87 43 44  
 levofloxacin (all dosed at 1g) 9 4 5  
 High dose moxifloxacin  
(>/=600mg) 
8 4 4  
 prothionamide 86 41 45  
 cycloserine 88 39 49  
 PAS 63 33 30  
 Linezolid (600mg od or bd) 35 14 21  
 clofazimine 14 6 8  
 clarithromycin or azithromycin 14 12 2  
 meropenem plus A/C 4 2 2  
 A/C 8 4 4  
 Bedaquiline*** 5 1 4  
Median duration of injectable agent, days  
(N=95)** 
(IQR) 
(Range) 
 182 
 
(109-208) 
(20-1070) 
166 
 
(106-192) 
(30-1070) 
184 
 
(119-229) 
(20-740) 
0.03 
Number initially discharged on DOT or VOT 
(n=81) 
 37 (46) 17 (37) 20 (57) 0.02 
Pulmonary surgery performed (n=100)  3 
n = number of cases for whom information is available, A/C=amoxicillin clavulanate, C=clofazimine, CS=cycloserine, E=ethambutol, 
FLQ=fluroquinolone, H=isoniazid, Li=linezolid, PAS= para-aminosalycylic acid, Pto=prothionamide, R= rifampicin, Z=pyrazinamide, 
IQR=interquartile range, DOT=directly observed therapy, VOT=video observed therapy. *A sub-optimal regimen was defined as under 4 
active drugs (original WHO groups 1-4 [4]plus clofazimine and linezolid). **Excludes 2 who were not treated with an injectable agent and 
the 3 recurrent defaulters in whom total duration of injectable was not available.***Bedaquiline was used in 4 cases of XDR-TB and in one 
case of MDR-TB where multiple drug intolerances led to 6 drugs being stopped. 
 
 
 
  
Table 5: Length of stay during initial hospital admission for 100 cases of MDR-TB diagnosed in London and West Midlands between 
2008 and 2014.  
Patient group Any PTB (%) Median duration 
of admission, days 
(IQR) 
Only EPTB (%) Median duration 
of admission, days 
(IQR) 
Patients admitted to 
hospital  
(n=100, PTB, 68 + 
EPTB, 32) 
 66/68* (97) 83 
IQR 44-116 
Range 6-513 
26/32 (81) 13 
IQR 7-34 
Range 3-250 
MDR-TB Type of 
those admitted 
 
MDR-TB (n=79) 50/52 (96) 84 
58-116 
23/27 (85) 
 
12.5 
6-30 
MDR-TB +FLQ (n=13) 10/10 (100) 50 
(18-241) 
1/3 (33) 55 
XDR-TB (n=8) 6/6 (100) 127 
(34-216) 
2/2 (100) 52.5 
(9-96) 
Microbiological 
status at discharge 
of those admitted to 
hospital~ 
(n=PTB,62+ EPTB, 
26) 
No sputum sent during 
admission 
1/62 (2) 10 
10-10 
12/26 (46) 9 
4-34 
Smear positive  4/62 (6) 15 
12-33 
0  - 
Smear negative 16/62 (26) 34.5 
21.5-56 
7/26 (27) 13 
7-24 
Smear negative plus 1 
negative culture 
12/62 (19) 87.5 
73.5-117.5 
5/26 (19) 36 
30-55 
Smear negative plus > 1 
negative culture 
26/62 (42) 115 
79-154 
2/26 (8) 129.5 
9-250 
no sputum within 70 
days from discharge’  
3 (5) 107 
94-112 
0  - 
Loss of home while 
an inpatient for 
those admitted**  
(n=PTB,65 + 
EPTB,26) 
 
 
 
 
10/65 (15) 
 
 
 
148.5 
83-184 
 
 
2/26 (8) 
 
 
 
65 
34-96 
 
 
Discharge location 
(n=PTB, 64 + EPTB, 
26) 
Home prior to admission 47/64 (73) 63 
31-92 
22/26 (85) 10 
6-24 
 New home organised by 
patient 
3/64 (5) 83 
66-106 
0 - 
 New home organised by 
hospital, council, CCG or 
PHE 
10/64 (15) 166.5 
132-216 
1/26 (4) 34 
 Prison 4/64 (6) 130.5 
95.5-197.5 
1/26 (4) 34 
 Transferred abroad 0 - 2/26 (8) 173 
96-250 
PTB=pulmonary TB, EPTB=extra-pulmonary only, MDR-TB= multidrug resistant tuberculosis, XDR-TB = extensively resistant tuberculosis, 
MDR-TB +FLQ= MDR-TB plus fluroquinolone resistance. ~See table 2 for definitions.  CCG=Care Commissioning Group, PHE=Public Health 
England, * not all patients were admitted to hospital as shown in this table, the two pulmonary cases that were not admitted were both 
smear negative. **home loss defined as having a home prior to admission to hospital.  
 
  
Table 6: Multivariable analysis of factors affecting length of hospital admission for 100 cases of MDR-TB diagnosed in London and West 
Midlands between 2008 and 2014. 
Variable Multivariable analysis 
Multiple imputation estimation 
 ESTIMATE*  
(95% CI) 
P-value 
Pulmonary TB (PTB) versus extra 
pulmonary TB (EPTB) 
2.78 (1.88-4.11) <0.001 
Presence of cavities verses no cavities on 
chest radiograph (data on all patients) 
1.78 (1.22-2.60) 0.003 
Lack of culture negative results verses 
smear and culture negative at discharge 
0.37 (0.26-0.52) <0.001 
Loss of home during admission verses no 
loss of home 
1.72 (1.07-2.76) 0.025 
CONSTANT** 26.62 (17.9-39.6)  <0.001 
* Estimates represent the multiple by which the geometric mean is multiplied.** The constant represents the geometric mean of length of 
stay for a patient who has extra-pulmonary TB (EPTB), with no cavities, who does not lose her home, and is culture negative on discharge.  
CI= confidence interval, MDR-TB= multidrug resistant tuberculosis. 
 
  
Table 7: Readmission to hospital  for 100 cases of MDR-TB diagnosed in London and West Midlands between 2008 and 2014. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represents 49 readmissions (28 patients), IRIS=immune reconstitution syndrome, LN =lymph node, TB=tuberculosis, MDR-TB= 
multidrug resistant tuberculosis. 
 
 
  
Reason for readmission (n=49) number of 
admissions 
Median duration in days 
(IQR)  
IRIS, LN enlargement, on-going TB investigations 6 6  (1-38) 
MDR-TB drug side effect related 18 4  (1-14) 
Medical other  4 4 (1.5-8.5) 
Culture reversion or potential for relapse as deemed by physician 10 143 (86-257) 
Line related (inc infection, changes, clots etc) 5 1 (1-1) 
Unknown/other 6 5 (1-9) 
Table 8- MDR-TB treatment outcomes for 100 cases of MDR-TB diagnosed in London and West Midlands between 2008 and 2014. 
Sputum culture conversion (cc) 
 
 
Total  
(% or IQR) 
 
MDR-TB  
(% or IQR) 
MDR-TB + 
FLQ (% or 
IQR) 
XDR-TB  
(% or IQR) 
Culture positive sputum 63 50 8 5 
Culture conversion documented* (n=63) 53/63 (84) 44/50 (88) 5/8 (62.5) 4/5 (80) 
Median time to culture conversion**, days (n=46) 33.5 (16-
55) 
34 (18-50) 3 (0-85) 48.5 (20-
72) 
Culture conversion by 60 days (n=46) 35/46 (76) 30/37 (81) 3/5 (60) 2/4 (50) 
Sputum culture reversion (n=63)*** 6/63 (10) 3/50 (6) 0  3/5 (60) 
End of treatment outcome**** Median duration on 
treatment, days (IQR) 
Total 
 
N=100  
MDR-TB (%) 
 
N=79 
MDR-TB + 
FLQr (%) 
N=13 
XDR-TB (%) 
 
N=8 
Successful Completed 720 (610-740) 74  58 (73) 10 (77)  6 (75) 
Neutral Transferred overseas 224 (197-425) 9 7 (9) 1 (8) 1 (13) 
 Deported/repatriation 279 (199-485) 3  3(4) 0  0  
Negative Lost to follow up - 0  0  0  0  
 Treatment stopped 389 (221-514) 8 6(8) 1 (7) 1 (13) 
 Recurrent defaulter - 3  2 (3) 1 (7) 0  
 Lost overseas 110 (20-200) 2  2 (3) 0  0  
 Died 69 1  1 (1) 0  0  
MDR-TB= multidrug resistant tuberculosis, XDR-TB = extensively resistant tuberculosis, MDR-TB +FLQ= MDR-TB plus fluroquinolone 
resistance, IQR=interquartile range. * Sputum culture conversion (CC) from positive is defined as the date of the first of two samples 
cultured to negativity taken at least 30 days apart, or culture negativity on one sample with no further samples and no positive samples in 
the 7 days prior. ** Time to CC was defined as the time between MDR-TB drug initiation and CC. *** Culture reversion (CR) to positive was 
defined as one sample that was culture positive taken over 30 days from the date of initial sputum CC or one positive sputum after the 
end of the injectable if CC not documented. (see Table 8 for characteristics).****Defined in Table 1. 
 
 
 
  
Table 9: Clinical details of sputum culture reversion cases and recurrent defaulter cases who were part of a cohort of 100 cases of MDR-
TB  
Case  MDR-TB 
Type 
Extent of 
pulmonary 
disease 
Time to CC 
(days) 
Time 
to CR 
(days  
from 
start of 
MDR-
TB Rx) 
Initial MDR-
TB regimen 
(final MDR-
TB regimen 
for cases 5 
and 6)  
Cause of reversion Repeat treatment Regimen after 
culture 
reversion 
outcome 
1 
 
XDR-TB 
 
 
Bilateral  
Disease 
+  
Cavities 
27 275 Cn, M (H), 
PAS, L, E, Z 
Poor adherence 
despite DOT,  alcohol 
excess, unsupported 
bed and breakfast 
accommodation 
Readmitted under legal 
order, discharged to 
supported 
accommodation  facility 
on DOT 
Cn, L, PAS, Cs, 
Li, C, A/A, B, Cl 
Completed at 
1069 days: 
deported 
once 
completed 
2* 
 
XDR-TB 
(starts 
with 
MDR-TB) 
Bilateral 
disease 
 
72 234 Cn, M, PAS, 
E, CS, Az 
Possible poor 
adherence once DOT 
stopped at 6 months, 
poor absorption due 
to chronic diarrhoea 
from PAS, poor drug 
penetration to cavity  
Treatment in DGH 
Readmitted voluntarily  
Left upper lobectomy 
Discharged home on 
DOT 
Ak, Cs, E, pto, C, 
Li, M/A,  
Completed at 
1092 days: 
no relapse at 
1 year.  
3** 
 
XDR-TB Bilateral  
Disease 
+  
Cavities 
cultures 
negative at 
282 + 
291.*** 
463 AK, Z, Pas, 
CS, C, Li, 
Mero/A, V 
non-resolving 
bronchopulmonary 
fistula.  
Adherence good. 
Readmitted voluntarily  
Surgical repair of 
bronchopulmonary 
fistula 
Discharged to a new 
home found by family 
Z, PAS, CS, C, Li, 
M/A, V 
Completed at 
1198 days. 
Well 3 
months later 
4 
 
MDR-TB Bilateral 
disease 
+  
Cavity  
15 352 Ak, M, P, 
Cs, Z, E 
large cavity 
adherence good 
Declined lobectomy and 
no further culture 
positive samples a year 
later and cavity resolved 
without further 
intervention. 
Ak, M, P, Cs, Z, 
E 
completed  
5 
 
MDR-TB Bilateral  
Disease 
+  
Cavities 
**** **** Ak/Cap, Z, 
E, L, Pto, CS 
Poor adherence.  Limited by ongoing poor 
adherence 
Ak/Cap, Z, E, M, 
Pto, CS 
Recurrent 
defaulter 
6 
 
MDR-TB Bilateral  
Disease 
+  
Cavities 
**** **** Cn, Pto, 
PAS, CS, Cl, 
Z,  
Poor adherence.  Limited by ongoing poor 
adherence 
Cn, Pto, PAS,  C, 
Z, Li 
Recurrent 
defaulter 
MDR-TB= multidrug resistant tuberculosis, XDR-TB = extensively resistant tuberculosis, MDR-TB +FLQ= MDR-TB plus fluroquinolone 
resistance, CC=culture conversion, CR=culture reversion, DOT=directly observed therapy, PTB=pulmonary TB, DGH=district general 
hospital, Rx=treatment, N/A= not applicable * treated at a DGH and then once XDR-TB occurred transferred to teaching hospital which 
was not one of the 4 centres, referred for surgery at centre 4. **treated at a DGH throughout with referral to centre 4 for surgery. 
Cn=capreomycin, AK=amikacin, M= moxifloxicin, L =levofloxacin, C= clofazemine, Cl=clarithromycin, Li=linezolid, A/A=amoxicillin and co-
amoxiclav, M/A=meropenem + co-amoxiclav, Z=pyrazinamide, E=ethambutol, H= high dose, B=bedaquiline (given for 6 months), 
Az=Azithromycin, Cs=cylcoserine, p=prothionamide, V=verapamil. ***sputum cultures not taken regularly before this point so it is 
unknown exact date culture conversion occurred. ****recurrently culture converting or only smear converting before default. 
NB-no cases were HIV positive. 
 
